Bevacizumab (Avastin) for the Treatment of Ocular Disease

Survey of Ophthalmology

Volumn 54, Issue 3, 2009, Pages 372-400

  Gunther, Jonathan B ^a   Altaweel, Michael M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Avastin; bevacizumab; intravitreal; macular degeneration; macular edema; neovascularization

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VERTEPORFIN;

ANEURYSM; ARTERY THROMBOSIS; BLEB FAILURE; BLEEDING; CAPILLARY HEMANGIOMA; CHORIORETINOPATHY; CHOROID MELANOMA; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL TRIAL; CORNEA NEOVASCULARIZATION; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRY EYE; EALES DISEASE; ENDOPHTHALMITIS; EXUDATIVE RETINITIS; GLAUCOMA; HEART INFARCTION; HUMAN; HYPERTENSIVE CRISIS; INTRAOCULAR PRESSURE; ISCHEMIC OPTIC NEUROPATHY; MELANOMA; MUCOUS MEMBRANE PEMPHIGOID; NEOVASCULAR GLAUCOMA; NEPHROTIC SYNDROME; NONHUMAN; OPTIC NERVE DISEASE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINOPATHY; REVIEW; STROKE; SUBRETINAL NEOVASCULARIZATION; TELANGIECTASIA; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; EYE DISEASES; HUMANS; INJECTIONS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 65349108729     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2009.02.004     Document Type: Review

References (270)

1. ___. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 102 10 (1995) 1434-1444
2. ___. Diabetic Retinopathy Clinical Research Network. A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema. Ophthalmology 114 (2007) 1860-1867
3. ___. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985) 1796-1806
4. ___. Evaluation of grid pattern photocoagulation for macular edem in central vein occlusion. The Central Vein Occlusion Study Group M Report. Ophthalmology 102 (1995) 1425-1433
5. ___. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central retinal vein occlusion: the Central Vein Occlusion Study Group M Report. Ophthalmology 102 (1995) 1425-1433
6. ___. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115 (1997) 486-491 [Erratum in: Arch Ophthalmol 1997;115:1275]
7. ___. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings. Diabetic Retinopathy Study (DRS) Report Number 8. Ophthalmology 88 (1981) 583-600
8. Abraham-Marin M.L., Cortes-Luna C.F., Alvarez-Rivera G., et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefe's Arch Clin Exp Ophthalmol 245 5 (2007) 651-655
9. Adán A., Mateo C., Navarro R., et al. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 27 9 (2007) 1180-1186
10. Adán A., Navarro M., Casaroli-Marano R.P., et al. Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefes Arch Clin Exp Ophthalmol 245 12 (2007) 1873-1875
11. Aggio F.B., Farah M.E., Silva Q.C., and Melo G.B. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefe's Arch Clin Exp Ophthalmol 245 (2007) 68-73
12. Ahmadieh H., Ramezani A., Shoeibi N., et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 246 4 (2008) 483-489
13. Ahmadieh H., and Vafi N. Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 45 11 (2007) 1731-1733
14. Aisenbrey S., Ziemssen F., Völker M., et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245 7 (2007) 941-948
15. American Society of Retina Specialists. Preferences And Trends Survey. Palm Springs, CA 2007
16. American Society of Retina Specialists. Preferences And Trends Survey (2006), France, Cannes
17. Amselem L., Cervera E., Díaz-Llopis M., et al. Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up. Eye 21 4 (2007) 566-567
18. Amselem L., Montero J., Diaz-Llopis M., et al. Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome. Am J Ophthalmol 144 1 (2007) 122-124
19. Apte R.S. Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to angioid streaks. Eye 22 5 (2008) 734-735
20. Arevalo J.F., Fromow-Guerra J., Quiroz-Mercado H., et al., Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114 4 (2007) 743-750
21. Arevalo J.F., Garcia-Amaris R.A., Roca J.A., et al., Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg 33 12 (2007) 2098-2105
22. Arevalo J.F., Maia M., Flynn Jr. H., et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92 2 (2008) 213-216
23. Arias L., Planas N., Prades S., et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 92 8 (2008) 1035-1039
24. Arriola-Villalobos P., Donate-Lopez J., Calvo-Gonzalez C., et al. Intravitreal bevacizumab (Avastin) for radiation retinopathy neovascularization. Acta Ophthalmol Scand 86 1 (2008) 115-116
25. Atmaca L., and Nagpal P.N. Eales' disease; medical, laser and surgical treatments. Ophthalmol Clin North Am 11 4 (1998) 619-626
26. Augustin A.J., Puls S., and Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 27 2 (2007) 133-140
27. Avery R.L., Pearlman J., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., Giust M.J., Wendel R., and Patel A. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 10 (2006) 1695 e1-15
28. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
29. Avery R.L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26 3 (2006) 352-354
30. Azad R., and Chandra P. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 55 4 (2007) 319
31. Bakri S.J., Donaldson M.J., and Link T.P. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye 20 12 (2006) 1474-1475
32. Bakri S.J., and Ekdawi N.S. Intravitreal triamcinolone and bevacizumab combination therapy for refractory choroidal neovascularization with retinal angiomatous proliferation. Eye 22 7 (2008) 978-980
33. Bashshur A.F., Bazarbachi A., Schakal A., et al. Intravitreal bevazicumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 (2006) 1-9
34. Bashshur Z.F., Haddad Z.A., Schakal A., et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145 2 (2008) 249-256
35. Bashshur Z.F., Schakal A., Hamam R.N., et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 125 10 (2007) 1357-1361
36. Batioglu F., Astam N., and Ozmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol 28 1 (2008) 59-61
37. Ben Yahia S., Herbort C.P., Jenzeri S., et al. Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. Int Ophthalmol 28 4 (2008) 311-316
38. Bennett J.L., Thomas S., Olson J.L., and Mandava N. Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. J Neuroophthalmol 27 3 (2007) 238-240
39. Bhatnagar P., Freund K.B., Spaide R.F., et al. Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 27 (2007) 897-902
40. Blinder K.J., Blumenkranz M.S., Bressler N.M., et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no 3. Ophthalmology 110 (2003) 667-673
41. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98 (1984) 271-282
42. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 14 (2006) 1432-1444
43. Cakir M., Cekiç O., and Yilmaz O.F. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. J AAPOS 12 3 (2008) 309-311
44. Cekic O., Chang S., Tseng J.J., et al. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 139 (2005) 993-998
45. Cekic O., Chang S., Tseng J.J., et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 25 (2005) 846-850
46. Chan W.M., Lai T.Y., Liu D.T., and Lam D.S. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 143 6 (2007) 977-983
47. Chan W.M., Lai T.Y., Liu D.T., and Lam D.S. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114 12 (2007) 2190-2196
48. Chan W.-M., Lam D.S.C., Lai T.Y.Y., et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87 12 (2003) 1453-1458
49. Chanana B., and Azad R.V. Intravitreal bevacizumab for macular edema secondary to retinal macroaneurysm. Eye 23 2 (2009) 493-494
50. Chang L.K., Spaide R.F., Brue C., et al. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 126 7 (2008) 941-945
51. Charbel Issa P., Finger R.P., Holz F.G., and Scholl H.P. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 92 7 (2008) 941-945
52. Chen C.Y., Wong T.Y., and Heriot W.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 143 3 (2007) 510-512
53. Chen E., and Park C.H. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26 6 (2006) 699-700
54. Chen K.J., Chen S.N., Kao L.Y., et al. Ocular ischemic syndrome. Chang Gung Med J 24 (2001) 483-491
55. Chung E.J., Kim J.H., Ahn H.S., and Koh H.J. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin(R)) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245 11 (2007) 1727-1730
56. Cleary C.A., Jungkim S., Ravikumar K., et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 22 1 (2008) 82-86
57. Cordero Coma M., Sobrin L., Onal S., et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114 8 (2007) 1574-1579
58. Cornish K.S., Ramamurthi S., Saidkasimova S., and Ramaesh K. Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye (2008) [Epub ahead of print]
59. Costa R.A., Jorge R., Calucci D., et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27 2 (2007) 141-149
60. Costa R.A., Jorge R., Calucci D., et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 245 9 (2007) 1273-1280
61. Costa R.A., Jorge R., Calucci D., et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 47 10 (2006) 4569-4578
62. Costagliola C., Romano M.R., dell'Omo R., et al. Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation. Am J Ophthalmol 144 3 (2007) 449-451
63. Cunningham Jr. E.T., Adamis A.P., Altaweel M., et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 10 (2005) 1747-1757
64. Das T., Biswas J., and Kumar A. Eales' disease. Indian J Ophthalmol 42 (1994) 3-18
65. Davidorf F.H., Mouser J.G., and Derick R.J. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 26 3 (2006) 354-356
66. de Klerk T.A., and Steel D.H. Use of intravitreal bevacizumab in a patient with a Von Hippel-Lindau-associated retinal haemangioblastoma of the optic nerve head: a case report. J Med Case Reports 2 (2008) 182
67. Dell'omo R., Kulkarni A., and Franks W.A. Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity. Acta Ophthalmol 86 6 (2008) 698-700
68. Derriman L., Marshall J., Moorman C., and Downes S.M. The use of intravitreal bevacizumab to treat choroidal neovascular membranes (CNVMs). Retina 28 6 (2008) 910 author reply 910-1
69. DeStafeno J.J., and Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 125 6 (2007) 834-836
70. Dhalla M., Shah G.K., Blinder K.J., et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 26 (2006) 988-993
71. Dorey C.K., Aouididi S., Reynaud X., et al. Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. Arch Ophthalmol 114 (1996) 1210-1217 [Erratum in: Arch Ophthalmol. 1997;115:192]
72. Duker J.S., and Brown G.C. The efficacy of panretinal photocoagulation for neovascularization of the iris after central retinal artery obstruction. Ophthalmology 96 1 (1989) 92-95
73. Ehlers J.P., Spirn M.J., and Lam A. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Set al. Retina 28 5 (2008) 696-702
74. Ehrlich R., Weinberger D., Priel E., and Axer-Siegel R. Outcome of bevacizumab (avastin) injection in patients with age-related macular degeneration and low visual acuity. Retina 28 9 (2008) 1302-1307
75. Emerson M.V., Lauer A.K., Flaxel C.J., et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27 4 (2007) 439-444
76. Erdurmus M., and Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245 10 (2007) 1577-1579
77. Eren E., Kucukerdonmez C., Yilmaz G., and Akova Y.A. Regression of neovascular posterior capsule vessels by intravitreal bevacizumab. J Cataract Refract Surg 33 6 (2007) 1113-1115
78. Falkenstein I.A., Cheng L., Morrison V.L., et al. Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina 27 6 (2007) 701-706
79. Fang X., Sakaguchi H., Gomi F., et al. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol 86 7 (2008) 800-805
80. Ferrara D.C., Koizumi H., and Spaide R.F. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 144 (2007) 864-871
81. Ficker L., Vafidis G., While A., and Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 72 11 (1988) 829-834
82. Figueroa M.S., Noval S., and Contreras I. Treatment of peripapillary choroidal neovascular membranes with intravitreal bevacizumab. Br J Ophthalmol 92 9 (2008) 1244-1247
83. Finger P.T., and Chin K. Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy. Arch Ophthalmol 125 6 (2007) 751-756
84. Finger P.T. Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. Am J Ophthalmol 143 2 (2007) 335-338
85. Finger P.T. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys 70 4 (2008) 974-977
86. Finger R.P., Charbel Issa P., Ladewig M., et al. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Br J Ophthalmol 92 4 (2008) 483-487
87. Flack A.J. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery (review). Trans Am Ophthalmol Soc 96 (1998) 557-634
88. Fung A.E., Lalwani G.A., Rosenfeld P.J., et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143 4 (2007) 566-583
89. Fung A.E., Rosenfeld P.J., and Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 11 (2006) 1344-1349
90. Gamulescu M.A., Walter A., Sachs H., and Helbig H. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 246 8 (2008) 1189-1193
91. Gass J.D., and Blodi B.A. Idiopathic juxtafoveolar retinal telangiectasis: update of classification and follow-up study. Ophthalmology 100 (1993) 1536-1546
92. Ghajarnia M., Kurup S., and Eller A. The therapeutic effects of intravitreal bevacizumab in a patient with recalcitrant idiopathic polypoidal choroidal vasculopathy. Semin Ophthalmol 22 2 (2007) 127-131
93. Ghazi N.G., Knape R.M., Kirk T.Q., et al. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation. Retina 28 5 (2008) 689-695
94. Gheith M.E., Siam G.A., de Barros D.S., et al. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 23 5 (2007) 487-491
95. Giansanti F., Virgili G., Bini A., et al. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 17 2 (2007) 230-237
96. Goff M.J., Johnson R.N., McDonald H.R., et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 27 4 (2007) 432-438
97. Gomi F., Nishida K., Oshima Y., et al. Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone. Am J Ophthalmol 143 3 (2007) 507-510
98. Gomi F., Sawa M., Sakaguchi H., et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 92 1 (2008) 70-73
99. Greenberg P.B., Martidis A., Rogers A.H., et al. Intravitreal triamcinolone acetonide for macular edema due to central retinal vein occlusion. Br J Ophthalmol 86 (2002) 247-248
100. Grisanti S., Biester S., Peters S., et al., Tuebingen Bevacizumab Study Group. Intravitreal bevacizumab (avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142 (2006) 158-160
101. Gündüz K., and Bakri S.J. Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Eye 22 9 (2008) 1168-1171
102. Gündüz K., Shields C.L., Shields J.A., et al. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 117 (1999) 609-614
103. Guthoff R., and Goebel W. Intravitreal bevacizumab for choroidal neovascularization in toxoplasmosis. Acta Ophthalmol (2008) [Epub ahead of print]
104. Haritoglou C., Kook D., Neubauer A., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26 9 (2006) 999-1005
105. Henderson B.A., Kim J.Y., Ament C.S., et al. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg 33 9 (2007) 1550-1558
106. Hernandez-Rojas M.L., Quiroz-Mercado H., Dalma-Weiszhausz J., et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27 6 (2007) 707-712
107. Honda S., Hirabayashi H., Tsukahara Y., and Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 246 7 (2008) 1061-1063
108. Hsu J., Kaiser R.S., Sivalingam A., et al. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina 27 8 (2007) 1013-1019
109. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 18 3 (2007) 235-239
110. Huang W.C., Chen W.L., Tsai Y.Y., et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eye 23 2 (2009) 488-499
111. Hughes M.S., and Sang D.N. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 37 (2006) 446-454
112. Iliev M.E., Domig D., Wolf-Schnurrbursch U., et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142 6 (2006) 1054-1056
113. Ip M.S., Gottlieb J.L., Kahana A., et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 122 (2004) 1131-1136
114. Ip M.S., and Kumar K.S. Intravitreal triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol 120 (2002) 1217-1219
115. Isaacs T.W., and Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 34 8 (2006) 802-803
116. Ishikawa K., Honda S., Tsukahara Y., and Negi A. A preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 23 1 (2009) 108-111
117. Iturralde D., Spaide R.F., Meyerle C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26 3 (2006) 279-284
118. Jaissle G.B., Leitritz M., Gelisken F., et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247 1 (2009) 27-33
119. Jaissle G.B., Ulmer A., Henke-Fahle S., et al. Suppression of melanoma-associated neoangiogenesis by bevacizumab. Arch Dermatol 144 4 (2008) 525-527
120. Jamerson S.C., Arunagiri G., Ellis B.D., and Leys M.J. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri. Int Ophthalmol (2008) 15 [Epub ahead of print]
121. Joeres S., Heussen F.M., Treziak T., et al. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 245 11 (2007) 1597-1602
122. Jonas S., and Rensch B. Schlichtenbrede. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 23 3 (2007) 240-242
123. Jonas J., Heatley G., Spaide R., and Varma R. Intravitreal triamcinolone acetonide and secondary ocular hypertension. J Glaucoma 14 (2005) 168-171
124. Jonas J.B., Kreissig I., and Degenring R.F. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240 (2002) 782-783
125. Jonas J.B., Libondi T., Ihloff A.K., et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 85 5 (2007) 563-565
126. Jonas J.B., Spandau U.H., and Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res 39 2 (2007) 121-122
127. Jorge R., Costa R.A., Calucci D., et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26 9 (2006) 1006-1013
128. Jorge R., Costa R.A., Calucci D., and Scott I.U. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 245 7 (2007) 1045-1048
129. Kahook M.Y., Schuman J.S., and Noecker R.J. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 37 2 (2006) 144-146
130. Kahook M.Y., Schuman J.S., and Noecker R.J. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 37 2 (2006) 148-150
131. Kang J.H., Park K.A., Chung S.E., and Kang S.W. Retinal angiomatous proliferation and intravitreal bevacizumab injection. Korean J Ophthalmol 21 4 (2007) 213-215
132. Kaushik S., Gupta V., Gupta A., et al. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol 137 (2004) 758-760
133. Kelman S.E. Intravitreal triamcinolone or bevacizumab for nonarteritic anterior ischemic optic neuropathy: do they merit further study?. J Neuroophthalmol 27 3 (2007) 161-163
134. Kenawy N., Groenwald C., and Damato B. Treatment of a vasoproliferative tumour with intravitreal bevacizumab (Avastin). Eye 21 6 (2007) 893-894
135. Kiss C., Michels S., Prager F., et al. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 26 8 (2006) 877-881
136. Kitnarong N., Chindasub P., and Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther 25 5 (2008) 438-443
137. Kreutzer T.C., Alge C.S., Wolf A.H., et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 92 3 (2008) 351-355
138. Kriechbaum K., Michels S., Prager F., et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92 4 (2008) 518-522
139. Küçükerdönmez C., Akova Y.A., and Yilmaz G. Intravitreal injection of bevacizumab in Eales disease. Ocul Immunol Inflamm 16 1 (2008) 63-65
140. Kumar A., and Sinha S. Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. Can J Ophthalmol 42 2 (2007) 335-336
141. Kurup S., Lew J., Byrnes G., et al. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. Acta Ophthalmol (2008) [Epub ahead of print]
142. Kusaka S., Shima C., Shimojyo H., Sato T., and Fujikado T. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 92 11 (2008) 1450-1455
143. Lai T.Y., Chan W.M., Liu D.T., et al. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 92 5 (2008) 661-666
144. Laud K., Spaide R.F., Freund K.B., et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26 8 (2006) 960-963
145. Lazic R., and Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245 1 (2007) 68-73
146. Lazic R., and Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114 6 (2007) 1179-1185
147. Lee S.Y., Kim J.G., Joe S.G., et al. The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol 22 2 (2008) 92-99
148. Leu J., Schrage N.F., and Degenring R.F. Choroidal neovascularisation secondary to Best's disease in a 13-year-old boy treated by intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 245 11 (2007) 1723-1725
149. Levy J., Shneck M., Rosen S., et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol (2008) [Epub ahead of print]
150. Lewis H., Abrams G.W., Blumenkranz M.S., and Campo R.V. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 99 5 (1992) 753-759
151. Lommatzsch A., Spital G., Trieschmann M., and Pauleikhoff D. [Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks.]. Ophthalmologe 104 4 (2007) 325-328
152. Luke M., Warga M., Ziemssen F., et al., Tuebingen Bevacizumab Study Group. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 90 9 (2006) 1178-1182
153. Mackensen F., Heinz C., Becker M.D., and Heiligenhaus A. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 28 1 (2008) 41-45
154. Maia Junior O.O., Bonanomi M.T., Takahashi W.Y., et al. Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia. Am J Ophthalmol 144 2 (2007) 296-299
155. Mandal S., Garg S., Venkatesh P., et al. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch Ophthalmol 125 11 (2007) 1487-1492
156. Mandal S., Venkatesh P., Abbas Z., et al. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 245 12 (2007) 1825-1829
157. Mandal S., Venkatesh P., Sampangi R., and Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17 4 (2007) 620-626
158. Mansour A.M., Mackensen F., Arevalo J.F., et al. Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization. Am J Ophthalmol 146 3 (2008) 410-416
159. Manzano R.P., Peyman G.A., Khan P., et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91 6 (2007) 804-807
160. Manzano R.P., Peyman G.A., Khan P., and Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 3 (2006) 257-261
161. Margolis R., Lowder C.Y., Sears J.E., and Kaiser P.K. Intravitreal bevacizumab for macular edema due to occlusive vasculitis. Semin Ophthalmol 22 2 (2007) 105-108
162. Markomichelakis N.N., Halkiadakis I., Pantelia E., et al. Patterns of macular edema in patients with uveitis. Qualitative and quantitative assessment using optical coherence tomography. Ophthalmlology 111 (2004) 946-953
163. Martidis A., Duker J.S., Greenberg P.B., et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109 5 (2002) 920-927
164. Mason J.O., Albert M.A., Mays A., and Vail R. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 26 7 (2006) 839-841
165. Mason J.O., Albert Jr. M.A., Persaud T.O., and Vail R.S. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina 27 7 (2007) 903-907
166. Mason J.O., Nixon P.A., and White M.F. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 142 4 (2006) 685-688
167. Mason J.O., Yunker J.J., Vail R., and McGwin Jr. G. Intravitreal bevacizumab (avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina 28 9 (2008) 1319-1324
168. Matsumoto Y., Freund K.B., Peiretti E., et al. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 27 4 (2007) 426-431
169. Maturi R.K., Bleau L.A., and Wilson D.L. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26 3 (2006) 270-274
170. McLeod D.S., Crone S.N., and Lutty G.A. Vasoproliferative in the neonatal dog model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 37 (1996) 1322-1333
171. Melamud A., Stinnett S., and Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 146 1 (2008) 91-95
172. Melo G.B., Farah M.E., and Aggio F.B. Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa. Acta Ophthalmol Scand 85 4 (2007) 461-463
173. Meyerle C.B., Freund K.B., Iturralde D., et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina 27 4 (2007) 451-457
174. Michels S., Rosenfeld P.J., Puliafito C.A., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 6 (2005) 1035-1047
175. Miller N.R. Radiation-induced optic neuropathy: still no treatment. Clin Experiment Ophthalmol 32 (2004) 233-235
176. Minnella A.M., Savastano C.M., Ziccardi L., et al. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 86 6 (2008) 683-687
177. Mintz-Hittner H.A., and Kuffel Jr. R.R. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28 6 (2008) 831-838
178. Mirshahi A., Roohipoor R., Lashay A., et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 18 2 (2008) 263-269
179. Mones J.M., Lopez M.A., Prieto J.A., and Rodriguez J.P. Extrafoveal choroidal neovascularization secondary to exudative age-related macular degeneration treated with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging 38 3 (2007) 226-228
180. Montero J.A., Ruiz-Moreno J.M., and De La Vega C. Intravitreal bevacizumab for adult-onset vitelliform dystrophy: a case report. Eur J Ophthalmol 17 6 (2007) 983-986
181. Moon S.J., Berger A.S., Tolentino M.J., and Misch D.M. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis. Ophthalmic Surg Lasers Imaging 38 2 (2007) 164-166
182. Moradian S., Ahmadieh H., Malihi M., et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246 12 (2008) 1699-1705
183. Moschos M.M., Brouzas D., Apostolopoulos M., et al. Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 114 1 (2007) 37-44
184. Moschos M.M., and Moschos M. Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol 116 2 (2008) 147-152
185. Moshfeghi A.A., Rosenfeld P.J., Puliafito C.A., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113 11 (2006) 1-12
186. Narayanan R., and Shah V.A. Intravitreal bevacizumab in the management of choroidal neovascular membrane secondary to choroidal osteoma. Eur J Ophthalmol 18 3 (2008) 466-468
187. Nguyen Q.D., Shah S., Tatlipinar S., et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89 10 (2005) 1368-1370
188. Ornek K., and Ornek N. Intravitreal bevacizumab treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther 24 4 (2008) 403-407
189. Oshima Y., Sakaguchi H., Gomi F., and Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142 1 (2006) 155-158
190. Ozkiri A. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema. Eye 23 3 (2009) 616-620
191. Paccola L., Costa R.A., Folgosa M.S., et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 92 1 (2008) 76-80
192. Pai S.A., Shetty R., Vijayan P.B., et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143 4 (2007) 601-606
193. Palmer E.A., Hardy R.J., Dobson V., et al. 15-year outcomes following threshold retinopathy of prematurity: final results from the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. Arch Ophthalmol 123 (2005) 311-318
194. Park D.W., Schatz H., McDonald H.R., and Johnson R.N. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 104 (1997) 1838-1846
195. Pedersen R., Soliman W., Lund-Andersen H., and Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 85 5 (2007) 526-533
196. Pierce E.A., Avery R.L., Foley E.D., et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92 (1995) 905-909
197. Priglinger S.G., Wolf A.H., Kreutzer T.C., et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 27 8 (2007) 1004-1012
198. Rabena M.D., Pieramici D.J., Castellarin A.A., et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27 4 (2007) 419-425
199. Rensch F., Spandau U.H., Schlichtenbrede F., et al. Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 39 3 (2008) 182-185
200. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevazicumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
201. Rinaldi M., Dell'Omo R., Romano M.R., et al. Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks. Arch Ophthalmol 125 10 (2007) 1422-1423
202. Rizzo S., Genovesi-Ebert F., Di Bartolo E., et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 246 6 (2008) 837-842
203. Rosen E., Rubowitz A., and Ferencz J.R. Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye (2008) [Epub ahead of print]
204. Rosenbaum J.T. Characterization of uveitis associated with spondyloarthritis. J Rheumatol 16 (1989) 792-796
205. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 14 (2006) 1419-1431
206. Rosenfeld P.J., Fung A.E., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36 4 (2005) 336-339
207. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 4 (2005) 331-335
208. Ruiz-Moreno J.M., Gomez-Ulla F., Montero J.A., et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye (2007) [Epub ahead of print]
209. Ruiz-Moreno J.M., and Montero J.A. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 12 2 (2002) 117-122
210. Ruys J., De Laey J.J., Vanderhaeghen Y., and Van Aken E.H. Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane. Eye 21 11 (2007) 1433-1434
211. Sachdev N., Vishwanathan K., Gupta V., et al. Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks. Indian J Ophthalmol 55 6 (2007) 457-458
212. Sakaguchi H., Ikuno Y., Gomi F., et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91 2 (2007) 161-165
213. Sangtam T., Vinekar A., Maheshwar B., et al. Intravitreal bevacizumab (Avastin) for post-laser photocoagulation anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 55 4 (2007) 317
214. Scartozzi R., Chao J.R., Walsh A.C., and Eliott D. Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection. Eye (2008) [Epub ahead of print]
215. Schadlu R., Blinder K.J., Shah G.K., et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 145 5 (2008) 875-878
216. Scott I.U., and Ip M.S. It's time for a clinical trial to investigate intravitreal triamcinolone for macular edema due to retinal vein occlusion: the SCORE Study. Arch Ophthalmol 123 (2005) 581-582
217. Secretan M., Kuhn D., Soubrane G., et al. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 7 (1997) 307-316
218. Shah P.K., Narendran V., Tawansy K.A., et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 55 1 (2007) 75-76
219. Shahar J., Avery R.L., Heilweil G., et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26 3 (2006) 262-269
220. Shaikh S. Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian J Ophthalmol 56 3 (2008) 259
221. Shanmugam M.P., Mythri H.M., and Shetty N.S. Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane. Indian J Ophthalmol 55 6 (2007) 490-491
222. Shetty R., Pai S.A., Vincent A., et al. Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 116 2 (2008) 129-135
223. Shields C.L., Demirci H., Dai V., et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina 25 (2005) 868-874
224. Shields C.L., Demirci H., Marr B.P., et al. Intravitreal triamcinolone acetonide for acute radiation papillopathy. Retina 26 5 (2006) 537-544
225. Shimura M., Nakazawa T., Yasuda K., et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 145 5 (2008) 854-861
226. Silva Paula J., Jorge R., Alves Costa R., et al. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 84 4 (2006) 556-557
227. Siqueira R.C., Costa R.A., Scott I.U., et al. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand 84 6 (2006) 834-835
228. Sivak-Callcott J.A., O'Day D.M., Gass D.M., and Tsai J.C. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 108 (2001) 1767-1776
229. Smith B.T., Dhalla M.S., Shah G.K., et al. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 28 5 (2008) 675-681
230. Smithen L.M., Ober M.D., Maranan L., and Spaide R.F. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 138 (2004) 740-743
231. Soheilian M., Ramezani A., Bijanzadeh B., et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 27 9 (2007) 1187-1195
232. Soliman W., Lund-Andersen H., and Larsen M. Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization. Acta Ophthalmol Scand 84 5 (2006) 707-708
233. Soliman W., Vinten M., Sander B., et al. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol 86 4 (2008) 365-371
234. Sothornwit N. Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma: a case report. J Med Assoc Thai 91 Suppl 1 (2008) S162-S165
235. Spaide R.F., and Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26 3 (2006) 275-278
236. Spaide R.F., Laud K., Fine J.F.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
237. Spandau U.H., Ihloff A.K., and Jonas J.B. Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 84 4 (2006) 555-556
238. Spandau U.H., and Jonas J.B. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization. Acta Ophthalmol Scand 85 3 (2007) 340-341
239. Spitzer M.S., Wallenfels-Thilo B., Sierra A., et al., Tuebingen Bevacizumab Study Group. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 90 10 (2006) 1316-1321
240. Spitzer M.S., Ziemssen F., Yoeruek E., et al. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 34 1 (2008) 70-75
241. Stahl A., Agostini H., Hansen L.L., and Feltgen N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245 10 (2007) 1429-1436
242. Stone J., Chan-Ling T., Pe'er J., et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 37 (1996) 290-299
243. Tabandeh H., Flynn Jr. H.W., Scott I.U., et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 106 (1999) 2063-2067
244. Teixeira A., Moraes N., Farah M.E., and Bonomo P.P. Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol Scand 84 6 (2006) 835-836
245. Tewari A., Dhalla M.S., and Apte R.S. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26 9 (2006) 1093-1094
246. Tonello M., Costa R.A., Almeida F.P., et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 86 4 (2008) 385-389
247. Torres-Soriano M.E., García-Aguirre G., Kon-Jara V., et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 246 9 (2008) 1235-1239
248. Tran T.H., Fardeau C., Terrada C., et al. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 246 12 (2008) 1685-1692
249. Travassos A., Teixeira S., Ferreira P., et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 38 3 (2007) 233-237
250. Uparkar M., Borse N., Kaul S., and Natarajan S. Photodynamic therapy following intravitreal bevacizumab in multifocal choroiditis. Int Ophthalmol 28 5 (2008) 375-377
251. Vatavuk Z., Bencic G., and Mandic Z. Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion. Eur J Ophthalmol 17 2 (2007) 269-271
252. Venkatesh P., Mandal S., and Garg S. Management of Coats disease with bevacizumab in 2 patients. Can J Ophthalmol 43 2 (2008) 245-246
253. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-Year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 108 (2001) 841-852
254. Vossmerbaeumer U., Spandau U.H., V Baltz S, et al. Intravitreal bevacizumab for choroidal neovascularisation secondary to punctate inner choroidopathy. Clin Experiment Ophthalmol 36 3 (2008) 292-294
255. Wakabayashi T., Oshima Y., Sakaguchi H., et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 115 9 (2008) 1571-1580
256. Weigert G., Michels S., Sacu S., et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 92 3 (2008) 356-360
257. Windisch R., and Kozousek V. Intravitreal bevacizumab compared with photodynamic therapy with verteporfin for group 2a parafoveal retinal telangiectasis. Can J Ophthalmol 43 4 (2008) 489-490
258. Wu L., Arevalo J.F., Roca J.A., et al., Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 28 2 (2008) 212-219
259. Wu L., Martinez-Castellanos M.A., Quiroz-Mercado H., et al., for the Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246 1 (2008) 81-87
260. Yamamoto I., Rogers A.H., Reichel E., et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91 2 (2007) 157-160
261. Yang C.M., Yeh P.T., Yang C.H., and Chen M.S. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 146 2 (2008) 211-217
262. Yannuzzi L.A., Negrao S., Iida T., et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 21 (2001) 416-434
263. Yanyali A., Aytug B., Horozoglu F., and Nohutcu A.F. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 144 1 (2007) 124-126
264. Yazdani S., Hendi K., and Pakravan M. Intravitreal bevacizumab (avastin) injection for neovascular glaucoma. J Glaucoma 16 5 (2007) 437-439
265. Yoganathan P., Deramo V.A., Lai J.C., et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26 (2006) 994-998
266. Yoshida T., Ohno-Matsui K., Yasuzumi K., et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 100 (2003) 1297-1305
267. Ziemssen F., Deuter C.M., Stuebiger N., and Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefe's Arch Clin Exp Ophthalmol 245 6 (2007) 917-918
268. Ziemssen F., Voelker M., Altpeter E., et al. Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma. Acta Ophthalmol Scand 85 5 (2007) 579-580
269. Ziemssen F., Voelker M., Inhoffen W., et al. Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. Eye 21 8 (2007) 1125-1126
270. Ziemssen F., Warga M., Neuhann I.M., et al. Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function?. Br J Ophthalmol 90 7 (2006) 922